Current Report Filing (8-k)
April 11 2023 - 8:01AM
Edgar (US Regulatory)
0001310527
false
0001310527
2023-04-10
2023-04-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (date of earliest event reported): April 10, 2023
QSAM
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
000-41337 |
|
20-1602779 |
(State
or other jurisdiction |
|
(Commission
File |
|
(IRS
Employer |
of
incorporation) |
|
Number) |
|
Identification
Number) |
9442
Capital of Texas Hwy N, Plaza 1, Suite 500 |
|
78759 |
(Address
of principal executive offices) |
|
(Zip
Code) |
|
|
|
Registrant’s
telephone number, including area code |
|
(512)
343-4558 |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
N/A |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD.
On
April 10, 2023, QSAM Biosciences, Inc. (the “Company”) posted an updated corporate presentation on its website, a copy of
which is being furnished as Exhibit 99.1 to this report and incorporated herein by reference. The Company may use the presentation, possibly
with modifications, in future presentations to current and potential investors, analysts, lenders, business partners, acquisition candidates,
customers, employees and others with an interest in the Company and its business.
A
copy of the presentation is available on the Company’s website at https://ir.qsambio.com/. Materials on the Company’s website
are not part of or incorporated by reference into this report.
In
accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall
not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
The
following exhibits are filed with this Current Report on Form 8-K:
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
April 11, 2023 |
QSAM
Biosciences, Inc. |
|
|
|
|
By: |
/s/
Douglas Baum |
|
|
Douglas
Baum |
|
|
Chief
Executive Officer |
Common Stock (QB) (USOTC:QSAM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Common Stock (QB) (USOTC:QSAM)
Historical Stock Chart
From Sep 2023 to Sep 2024